Analysts at StockNews.com began coverage on shares of Aethlon Medical (NASDAQ:AEMD – Get Free Report) in a report issued on Saturday. The firm set a “sell” rating on the medical equipment provider’s stock.
Separately, HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Aethlon Medical in a research report on Friday.
Check Out Our Latest Stock Analysis on AEMD
Aethlon Medical Trading Up 0.2 %
Aethlon Medical Company Profile
Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.
Read More
- Five stocks we like better than Aethlon Medical
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Warren Buffett, Cathie Wood Own Nu Holdings, Should You?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?
- 10 Best Airline Stocks to Buy
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.
